Ranbaxy Allergy Medicine Recall: Company Brings Back 29,790 For Defective Packaging

Pharmaceutical company Ranbaxy has recalled 29,790 packs of over-the-counter allergy medication due to defective packaging issues.

The affected medications include 10 and 240 milligrams of loratadine and pseudoephedrine sulfate extended release tablets, according to the United States Food and Drug Administration's recall information.

"An unacceptable level of blister defects have been identified in loratadine and pseudoephedrine sulfate extended release tablets," the USFDA said.

The affected products were sold at drug stores in California, Ohio, Pennsylvania, Rhode Island, and Texas.

Stores selling the product included Krogers, Mckesson, AmerisourceBergen, H-E-B, and Rite Aid. CVS Pharmacy shipped them to the pharmacies.

The medication bears the lot numbers 2554936, and 2554938. The products are set to expire Sept. 2015.

According to Monthly Prescribing Reference, the capsules treat allergic rhinitis with nasal congestion in adults.

Consumers can call the administration at 866-463-6332 with questions.

According to Zeenews India, The USFDA forbade New Delhi-based company Ranbaxy's four plants from sending drug products to the United States.

The administration issued another ban disallowing the company from shipping active pharmaceutical ingredients from a plant in Toansa, India.

According to an administration press release, FDA's acting director of the Office of Compliance in the agency's center for drug evaluation and research said the agency aimed to approach the situation proactively.

"We are taking swift action to prevent substandard quality products from reaching U.S. consumers," Carol Bennett said at the time. "The FDA is committed to ensuring that the drugs American consumers receive - no matter where they are produced - meet quality standards and are safe and effective."

The FDA also reportedly placed an import alert on the company's Mohali plant in Punjab, Sept 2013. Employees at the plant breached standards for making products Zeenews reported.

Ranbaxy's Paonta Sahib facility in Himachal Pradesh, India has been on alert since 2008. This also includes Dewas in the Madhya Pradesh Indian state.

The company pleaded guilty to felony charges in May 2013. These dealt with the products manufacturing and shipment.

Real Time Analytics